[Therapeutic effect and effect on the pituitary adrenal functions of fluocortine-butylester in eczema during childhood (author's transl)].
A new topical corticosteroid: fluocortin-butylester, was employed in 11 eczematous children (atopic and seborrhoeic dermatitis), with a good clinical result. These topical applications involve no significant risk of interference with the pituitary-adrenal function.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D012628:Dermatitis, Seborrheic / Q000188:drug therapy*; D004341:Drug Evaluation; D005448:Fluocortolone / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007223:Infant; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011244:Pregnadienediols / Q000627:therapeutic use*
D011244:Pregnadienediols; D005448:Fluocortolone; D006854:Hydrocortisone
Effet thérapeutique et effet sur la fonction cortico-surrénale du fluocortine-butylester dans l'eczéma de l'enfant.